Andra AP fonden Has $13.69 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Andra AP fonden lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 43.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 100,300 shares of the company's stock after selling 77,600 shares during the quarter. Andra AP fonden owned 0.10% of Neurocrine Biosciences worth $13,691,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of NBIX. Raymond James Financial Inc. purchased a new position in Neurocrine Biosciences in the 4th quarter valued at about $115,193,000. State Street Corp boosted its position in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company's stock valued at $593,186,000 after purchasing an additional 539,936 shares during the period. Jennison Associates LLC boosted its stake in Neurocrine Biosciences by 145.1% during the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company's stock valued at $112,025,000 after purchasing an additional 485,894 shares during the period. Los Angeles Capital Management LLC raised its stake in Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock valued at $48,479,000 after acquiring an additional 363,863 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its holdings in Neurocrine Biosciences by 207.8% in the fourth quarter. Impax Asset Management Group plc now owns 261,599 shares of the company's stock worth $35,708,000 after purchasing an additional 176,599 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Remove Ads

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the company's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the sale, the insider now directly owns 2,507 shares of the company's stock, valued at approximately $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Charles Gorman sold 5,844 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now directly owns 521,618 shares of the company's stock, valued at approximately $60,867,604.42. The trade was a 1.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 234,269 shares of company stock valued at $34,053,879 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded up $1.85 during mid-day trading on Wednesday, reaching $109.07. The company's stock had a trading volume of 1,342,510 shares, compared to its average volume of 1,350,951. The firm's 50-day moving average is $131.36 and its two-hundred day moving average is $126.41. Neurocrine Biosciences, Inc. has a 1-year low of $105.18 and a 1-year high of $157.98. The company has a market cap of $10.87 billion, a P/E ratio of 33.15, a PEG ratio of 0.77 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its Board of Directors has initiated a stock buyback program on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several recent research reports. Royal Bank of Canada lowered their price objective on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group cut their price target on Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating for the company in a research note on Friday, February 7th. HC Wainwright restated a "buy" rating and issued a $185.00 price objective on shares of Neurocrine Biosciences in a report on Friday, February 21st. Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 11th. They set a "hold" rating and a $138.00 price target on the stock. Finally, Piper Sandler reiterated an "overweight" rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $165.24.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.